Targeting the AHR–IDO1–kynurenine pathway in TREM2+ macrophages restores antitumor immunity in thyroid cancer - Takeaways - MDSpire

Modulating the AHR–IDO1–kynurenine axis in TREM2+ macrophages enhances antitumor immune responses in thyroid carcinoma

  • By

  • Fei Le

  • Xianming Huang

  • Youfang Jiang

  • Saiping Lv

  • Yaoyao Chen

  • July 21, 2026

Share

  • 1

    TREM2+ tumor-associated macrophages are enriched in the thyroid cancer immune microenvironment and exhibit immunosuppressive profiles.

  • 2

    These macrophages activate the AHR–IDO1–kynurenine signaling axis, impairing CD8+ T-cell function and promoting immune evasion.

  • 3

    Pharmacological inhibition of AHR and IDO1 can reverse immune suppression and reduce tumor burden in experimental models.

  • 4

    The study utilized integrated single-cell multi-omics approaches to characterize TREM2+ macrophages in thyroid cancer.

  • 5

    Targeting the AHR–IDO1–kynurenine pathway may enhance antitumor immunity and improve therapeutic strategies for thyroid cancer.

Original Source(s)

Targeting the AHR–IDO1–kynurenine pathway in TREM2+ macrophages restores antitumor immunity in thyroid cancer

  • by Fei Le, Xianming Huang, Youfang Jiang, Saiping Lv, Yaoyao Chen

  • July 21, 2026

Related Content

Radiomics and clinical data predict pseudoprogression after radiotherapy in high-grade glioma

Prognostic analysis of first-recurrence/metastasis esophageal squamous cell carcinoma: chemoimmunotherapy combined with radiotherapy as one of the optimal clinical management strategies

Spatial immune ecology of immunotherapy resistance in gastric and gastroesophageal junction adenocarcinoma